NADPH Oxidases in Parkinson's Disease
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Novel Binding Partners of PBF in Thyroid Tumourigenesis
NOVEL BINDING PARTNERS OF PBF IN THYROID TUMOURIGENESIS By Neil Sharma A thesis presented to the College of Medical and Dental Sciences at the University of Birmingham for the Degree of Doctor of Philosophy Centre for Endocrinology, Diabetes and Metabolism, School of Clinical and Experimental Medicine August 2013 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. SUMMARY Thyroid cancer is the most common endocrine cancer, with a rising incidence. The proto-oncogene PBF is over-expressed in thyroid tumours, and the degree of over-expression is directly linked to patient survival. PBF causes transformation in vitro and tumourigenesis in vivo, with PBF-transgenic mice developing large, macro-follicular goitres, effects partly mediated by the internalisation and repression of the membrane-bound transporters NIS and MCT8. NIS repression leads to a reduction in iodide uptake, which may negatively affect the efficacy of radioiodine treatment, and therefore prognosis. Work within this thesis describes the use of tandem mass spectrometry to produce a list of potential binding partners of PBF. This will aid further research into the pathophysiology of PBF, not just in relation to thyroid cancer but also other malignancies. -
Mouse Germ Line Mutations Due to Retrotransposon Insertions Liane Gagnier1, Victoria P
Gagnier et al. Mobile DNA (2019) 10:15 https://doi.org/10.1186/s13100-019-0157-4 REVIEW Open Access Mouse germ line mutations due to retrotransposon insertions Liane Gagnier1, Victoria P. Belancio2 and Dixie L. Mager1* Abstract Transposable element (TE) insertions are responsible for a significant fraction of spontaneous germ line mutations reported in inbred mouse strains. This major contribution of TEs to the mutational landscape in mouse contrasts with the situation in human, where their relative contribution as germ line insertional mutagens is much lower. In this focussed review, we provide comprehensive lists of TE-induced mouse mutations, discuss the different TE types involved in these insertional mutations and elaborate on particularly interesting cases. We also discuss differences and similarities between the mutational role of TEs in mice and humans. Keywords: Endogenous retroviruses, Long terminal repeats, Long interspersed elements, Short interspersed elements, Germ line mutation, Inbred mice, Insertional mutagenesis, Transcriptional interference Background promoter and polyadenylation motifs and often a splice The mouse and human genomes harbor similar types of donor site [10, 11]. Sequences of full-length ERVs can TEs that have been discussed in many reviews, to which encode gag, pol and sometimes env, although groups of we refer the reader for more in depth and general infor- LTR retrotransposons with little or no retroviral hom- mation [1–9]. In general, both human and mouse con- ology also exist [6–9]. While not the subject of this re- tain ancient families of DNA transposons, none view, ERV LTRs can often act as cellular enhancers or currently active, which comprise 1–3% of these genomes promoters, creating chimeric transcripts with genes, and as well as many families or groups of retrotransposons, have been implicated in other regulatory functions [11– which have caused all the TE insertional mutations in 13]. -
Unexpected Intracellular Biodegradation and Recrystallization
Unexpected intracellular biodegradation and recrystallization of gold nanoparticles Alice Balfouriera, Nathalie Luciania, Guillaume Wangb, Gerald Lelongc, Ovidiu Ersend, Abdelali Khelfab, Damien Alloyeaub, Florence Gazeaua,1,2 , and Florent Carna,1,2 aLaboratoire Matiere` et Systemes` Complexes, CNRS, Universite´ de Paris, Paris 75205 Cedex 13, France; bLaboratoire Materiaux´ et Phenom´ enes` Quantiques, CNRS, Universite´ de Paris, Paris 75205 Cedex 13, France; cMuseum´ National d’Histoire Naturelle, CNRS, Institut de Recherche pour le Developpement´ (IRD), Institut de Mineralogie,´ de Physique des Materiaux´ et de Cosmochimie, Sorbonne Universite,´ Paris 75005, France; and dInstitut de Physique et Chimie des Materiaux´ de Strasbourg, Universite´ de Strasbourg, CNRS, Strasbourg 67087, France Edited by Catherine J. Murphy, University of Illinois at Urbana–Champaign, Urbana, IL, and approved November 18, 2019 (received for review July 10, 2019) Gold nanoparticles are used in an expanding spectrum of biomed- processes have been described for metal or metal oxide nanopar- ical applications. However, little is known about their long-term ticles, but only few concern GNPs (23–25). As a noble metal, gold fate in the organism as it is generally admitted that the inert- is more inert, less sensitive to acidic environment, and less reac- ness of gold nanoparticles prevents their biodegradation. In this tive than most other metals and metal oxide (26). Therefore, the work, the biotransformations of gold nanoparticles captured by current dogma is that the inertness of gold prevents biodegra- primary fibroblasts were monitored during up to 6 mo. The combi- dation of gold implants or GNPs that could be left indefinitely nation of electron microscopy imaging and transcriptomics study intact in tissues. -
2020.05.13.092460V1.Full.Pdf
bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092460; this version posted May 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. An adaptive pre-DNA-damage-response protects genome integrity Sandrine Ragu1,2, Gabriel Matos-Rodrigues1,2, Nathalie Droin3, Aurélia Barascu1, Sylvain Caillat4, Gabriella Zarkovic5, Capucine Siberchicot6, Elodie Dardillac1,2, Camille Gelot1, Juan Pablo Radicella6, Alexander A. Ishchenko5, Jean-Luc Ravanat4, Eric Solary3 and Bernard S. Lopez1,2 * 1Institut Cochin, INSERM U1016, UMR 8104 CNRS, Université de Paris, Paris-Descartes, Equipe Labellisée Ligue Contre le Cancer 24 rue du Faubourg St Jacques, 75014 Paris, France 2CNRS UMR 8200, Institut de Cancérologie Gustave-Roussy, Université Paris Saclay, 114 Rue Edouard Vaillant, 94805 Villejuif, France. 3Institut de Cancérologie Gustave-Roussy, INSERM U1170, Université Paris Saclay, Equipe Labellisée Ligue Contre le Cancer 114 Rue Edouard Vaillant, 94805 Villejuif, France. 4CEA, INAC-SCIB-LAN, Université Grenoble Alpes, F-38000 Grenoble. 5 Groupe «Réparation de l'ADN», Equipe Labellisée par la Ligue Nationale contre le Cancer, CNRS UMR 8200, Gustave Roussy, Université Paris Saclay, F-94805 Villejuif, France 6Institute of Cellular and Molecular Radiobiology, Inst. de Biologie François Jacob, CEA, Université de Paris, Université Paris-Saclay, F-92260 Fontenay aux Roses, France *Correspondence to: Bernard S. Lopez. [email protected] Running title: Adapt cell response to stress severity 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.092460; this version posted May 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. -
Natural Course of Congenital Hypothyroidism by Dual Oxidase 2 Mutations from the Neonatal Period Through Puberty
Y Maruo and others Clinical features of DUOX2 174:4 453–463 Clinical Study defects Natural course of congenital hypothyroidism by dual oxidase 2 mutations from the neonatal period through puberty Yoshihiro Maruo1, Keisuke Nagasaki, Katsuyuki Matsui, Yu Mimura, Asami Mori, Maki Fukami2 and Yoshihiro Takeuchi Correspondence should be addressed Department of Pediatrics, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Shiga 520-2192, Japan, to Y Maruo 1Department of Pediatrics, Niigata University, Niigata, Japan and 2Department of Molecular Endocrinology, Email National Research Institute for Child Health and Development, Tokyo, Japan [email protected] Abstract Aim: We previously reported that biallelic mutations in dual oxidase 2 (DUOX2) cause transient hypothyroidism. Since then, many cases with DUOX2 mutations have been reported. However, the clinical features and prognosis of individuals with DUOX2 defects have not been clarified. Objective: We investigated the prognosis of patients with congenital hypothyroidism (CH) due to DUOX2 mutations. Patients: Twenty-five patients were identified by a neonatal screening program and included seven familial cases. Their serum TSH values ranged from 18.9 to 734.6 mU/l. Twenty-two of the patients had low serum free thyroxine (fT4) levels (0.17–1.1 ng/dl). Twenty-four of the patients were treated with L-thyroxine. Methods: We analyzed the DUOX2, thyroid peroxidase, NaC/IK symporter, and dual oxidase maturation factor 2 genes of these 25 patients by PCR-amplified direct sequencing. An additional 11 genes were analyzed in 11 of the 25 patients using next-generation sequencing. Results: All patients had biallelic DUOX2 mutations, and seven novel alleles were detected. -
Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase -
Identifizierung Und Charakterisierung Von T-Zell-Definierten Antigenen
Identifizierung und Charakterisierung von Zielantigenen alloreaktiver zytotoxischer T-Zellen mittels cDNA-Bank-Expressionsklonierung in akuten myeloischen Leukämien Dissertation zur Erlangung des Grades Doktor der Naturwissenschaften am Fachbereich Biologie der Johannes Gutenberg-Universität Mainz Sabine Domning Mainz, 2012 Fachbereich Biologie der Johannes Gutenberg-Universität Mainz Dekan: 1.Berichterstatter: 2.Berichterstatter: Tag der mündlichen Prüfung: ZUSAMMENFASSUNG Zusammenfassung Allogene hämatopoetische Stammzelltransplantationen (HSZTs) werden insbesondere zur Behandlung von Patienten mit Hochrisiko-Leukämien durchgeführt. Dabei bewirken T- Zellreaktionen gegen Minorhistokompatibilitätsantigene (mHAgs) sowohl den therapeutisch erwünschten graft-versus-leukemia (GvL)-Effekt als auch die schädigende graft-versus-host (GvH)- Erkrankung. Für die Identifizierung neuer mHAgs mittels des T-Zell-basierten cDNA- Expressionsscreenings waren leukämiereaktive T-Zellpopulationen durch Stimulation naïver CD8+- T-Lymphozyten gesunder HLA-Klasse I-identischer Buffy Coat-Spender mit Leukämiezellen von Patienten mit akuter myeloischer Leukämie (AML) generiert worden (Albrecht et al., Cancer Immunol. Immunother. 60:235, 2011). Im Rahmen der vorliegenden Arbeit wurde mit diesen im AML-Modell des Patienten MZ529 das mHAg CYBA-72Y identifiziert. Es resultiert aus einem bekannten Einzelnukleotidpolymorphismus (rs4673: CYBA-242T/C) des Gens CYBA (kodierend für Cytochrom b-245 α-Polypeptid; syn.: p22phox), der zu einem Austausch von Tyrosin (Y) zu Histidin (H) an Aminosäureposition 72 führt. Das mHAg wurde von T-Lymphozyten sowohl in Assoziation mit HLA-B*15:01 als auch mit HLA-B*15:07 erkannt. Eine allogene T-Zellantwort gegen CYBA-72Y wurde in einem weiteren AML-Modell (MZ987) beobachtet, die ebenso wie in dem AML-Modell MZ529 polyklonal war. Insgesamt konnte bei drei von fünf getesteten HLA-B*15:01-positiven Buffy Coat-Spendern, die homozygot für CYBA-72H (H/H) waren, eine CYBA-72Y-spezifische T- Zellantwort generiert werden. -
Figure S1. HAEC ROS Production and ML090 NOX5-Inhibition
Figure S1. HAEC ROS production and ML090 NOX5-inhibition. (a) Extracellular H2O2 production in HAEC treated with ML090 at different concentrations and 24 h after being infected with GFP and NOX5-β adenoviruses (MOI 100). **p< 0.01, and ****p< 0.0001 vs control NOX5-β-infected cells (ML090, 0 nM). Results expressed as mean ± SEM. Fold increase vs GFP-infected cells with 0 nM of ML090. n= 6. (b) NOX5-β overexpression and DHE oxidation in HAEC. Representative images from three experiments are shown. Intracellular superoxide anion production of HAEC 24 h after infection with GFP and NOX5-β adenoviruses at different MOIs treated or not with ML090 (10 nM). MOI: Multiplicity of infection. Figure S2. Ontology analysis of HAEC infected with NOX5-β. Ontology analysis shows that the response to unfolded protein is the most relevant. Figure S3. UPR mRNA expression in heart of infarcted transgenic mice. n= 12-13. Results expressed as mean ± SEM. Table S1: Altered gene expression due to NOX5-β expression at 12 h (bold, highlighted in yellow). N12hvsG12h N18hvsG18h N24hvsG24h GeneName GeneDescription TranscriptID logFC p-value logFC p-value logFC p-value family with sequence similarity NM_052966 1.45 1.20E-17 2.44 3.27E-19 2.96 6.24E-21 FAM129A 129. member A DnaJ (Hsp40) homolog. NM_001130182 2.19 9.83E-20 2.94 2.90E-19 3.01 1.68E-19 DNAJA4 subfamily A. member 4 phorbol-12-myristate-13-acetate- NM_021127 0.93 1.84E-12 2.41 1.32E-17 2.69 1.43E-18 PMAIP1 induced protein 1 E2F7 E2F transcription factor 7 NM_203394 0.71 8.35E-11 2.20 2.21E-17 2.48 1.84E-18 DnaJ (Hsp40) homolog. -
Interstitial Deletion of 6Q25.2&Ndash
European Journal of Human Genetics (2009) 17, 573 – 581 & 2009 Macmillan Publishers Limited All rights reserved 1018-4813/09 $32.00 www.nature.com/ejhg ARTICLE Interstitial deletion of 6q25.2–q25.3: a novel microdeletion syndrome associated with microcephaly, developmental delay, dysmorphic features and hearing loss Sandesh Chakravarthy Sreenath Nagamani1, Ayelet Erez1, Christine Eng1, Zhishuo Ou1, Craig Chinault1, Laura Workman2, James Coldwell3, Pawel Stankiewicz1, Ankita Patel1, James R Lupski1,4,5 and Sau Wai Cheung*,1 1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA; 2Sutter Medical Center, Sacramento, CA, USA; 3Children’s Medical Center, Tulsa, OK, USA; 4Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; 5Texas Children’s Hospital, Houston, TX, USA Interstitial deletions of 6q are rare. We report a detailed clinical and molecular characterization of four patients with interstitial deletion involving 6q25. All of our patients presented with microcephaly, developmental delay, dysmorphic features and hearing loss, whereas two of them had agenesis of the corpus callosum. We determined the size, extent and genomic content of the deletions using high-density array-comparative genomic hybridization (a-CGH), and found that a common segment spanning 3.52 Mb within the 6q25.2–q25.3 region was deleted in all four cases. We hypothesize that a subset of genes in the commonly deleted region are dosage sensitive and that haploinsufficieny of these genes impairs normal development of the brain and hearing. European Journal of Human Genetics (2009) 17, 573–581; doi:10.1038/ejhg.2008.220; published online 26 November 2008 Keywords: 6q deletion; hearing loss; microcephaly, developmental delay; agenesis of the corpus callosum; array-CGH Introduction lips, a lower frequency of microcephaly, micrognathia Since the first reported case in 1975,1 over 65 cases of and heart malformations. -
Loci for Phenotypic Dispersion in Plasma Leptin in Mouse Models of Diabetes Mellitus
RESEARCH ARTICLE `Fat's chances': Loci for phenotypic dispersion in plasma leptin in mouse models of diabetes mellitus Guy M. L. PerryID* Department of Biology, University of Prince Edward Island, Charlottetown, PEI, Canada * [email protected] a1111111111 a1111111111 a1111111111 Abstract a1111111111 Background a1111111111 Leptin, a critical mediator of feeding, metabolism and diabetes, is expressed on an incidental basis according to satiety. The genetic regulation of leptin should similarly be episodic. Methodology OPEN ACCESS Data from three mouse cohorts hosted by the Jackson Laboratory± 402 (174F, 228M) F Citation: Perry GML (2019) `Fat's chances': Loci 2 for phenotypic dispersion in plasma leptin in Dilute Brown non-Agouti (DBA/2)×DU6i intercrosses, 142 Non Obese Diabetic (NOD/ g7 mouse models of diabetes mellitus. PLoS ONE 14 ShiLtJ×(NOD/ShiLtJ×129S1/SvImJ.H2 ) N2 backcross females, and 204 male Nonobese (10): e0222654. https://doi.org/10.1371/journal. Nondiabetic (NON)×New Zealand Obese (NZO/HlLtJ) reciprocal backcrosses±were used pone.0222654 to test for loci associated with absolute residuals in plasma leptin and arcsin-transformed Editor: Clemens FuÈrnsinn, Medical University of percent fat (`phenotypic dispersion'; PDpLep and PDAFP). Individual data from 1,780 mice Vienna, AUSTRIA from 43 inbred strains was also used to estimate genetic variances and covariances for dis- Received: April 1, 2019 persion in each trait. Accepted: September 4, 2019 Published: October 29, 2019 Principal findings Copyright: © 2019 Guy M. L. Perry. This is an open Several loci for PDpLep were detected, including possibly syntenic Chr 17 loci, but there was access article distributed under the terms of the only a single position on Chr 6 for PDAFP. -
Datasheet A03090 Anti-NOX5 Antibody
Product datasheet Anti-NOX5 Antibody Catalog Number: A03090 BOSTER BIOLOGICAL TECHNOLOGY Special NO.1, International Enterprise Center, 2nd Guanshan Road, Wuhan, China Web: www.boster.com.cn Phone: +86 27 67845390 Fax: +86 27 67845390 Email: [email protected] Basic Information Product Name Anti-NOX5 Antibody Gene Name NOX5 Source Rabbit IgG Species Reactivity human Tested Application WB,FCM,Direct ELISA,ICC/IF Contents 500ug/ml antibody with PBS ,0.02% NaN3 , 1mg BSA and 50% glycerol. Immunogen E. coli-derived human NOX5 recombinant protein (Position: E13-F197). Purification Immunogen affinity purified. Observed MW 86KD Dilution Ratios Western blot: 1:500-2000 Flow Cytometry: 1-3μg/1x106 cells Direct ELISA: 1:100-1000 Immunocytochemistry/Immunofluorescence (ICC/IF): 1:50-400 Storage 12 months from date of receipt,-20℃ as supplied.6 months 2 to 8℃ after reconstitution. Avoid repeated freezing and thawing Background Information NOX5(Nadph Oxidase 5), also known as NOX5A or NOX5B, is a protein which in humans is encoded by the NOX5 gene. The International Radiation Hybrid Mapping Consortium mapped the NOX5 gene to chromosome 15. NOX5 is a novel NADPH oxidase that generates superoxide and functions as an H+ channel in a Ca2+-dependent manner. It is found that, when heterologously expressed, NOX5 was quiescent in unstimulated cells. However, in response to elevations of the cytosolic Ca2+ concentration, it generated large amounts of superoxide. Using RT- PCR and Southern and Western blot analyses, NOX5 was identified as a flavin-containing Ca2+-dependent oxidase present in hairy leukemic cells (HC), but not normal B cells. Reference Anti-NOX5 Antibody被引用在1文献中。 CRISPR-Cas9 Mediated NOX4 Knockout Inhibits Cell Proliferation and Invasion in HeLa Cells | Jafari N, Kim H, PubMed:28099519 Park R, Li L, Jang M, Morris AJ, Park J, Huang C. -
DUOX1 Mediates Persistent Epithelial EGFR Activation, Mucous Cell Metaplasia, and Airway Remodeling During Allergic Asthma
DUOX1 mediates persistent epithelial EGFR activation, mucous cell metaplasia, and airway remodeling during allergic asthma Aida Habibovic, … , Miklos Geiszt, Albert van der Vliet JCI Insight. 2016;1(18):e88811. https://doi.org/10.1172/jci.insight.88811. Research Article Inflammation Pulmonology Chronic inflammation with mucous metaplasia and airway remodeling are hallmarks of allergic asthma, and these outcomes have been associated with enhanced expression and activation of EGFR signaling. Here, we demonstrate enhanced expression of EGFR ligands such as amphiregulin as well as constitutive EGFR activation in cultured nasal epithelial cells from asthmatic subjects compared with nonasthmatic controls and in lung tissues of mice during house dust mite–induced (HDM-induced) allergic inflammation. EGFR activation was associated with cysteine oxidation within EGFR and the nonreceptor tyrosine kinase Src, and both amphiregulin production and oxidative EGFR activation were diminished by pharmacologic or genetic inhibition of the epithelial NADPH oxidase dual oxidase 1 (DUOX1). DUOX1 deficiency also attenuated several EGFR-dependent features of HDM-induced allergic airway inflammation, including neutrophilic inflammation, type 2 cytokine production (IL-33, IL-13), mucous metaplasia, subepithelial fibrosis, and central airway resistance. Moreover, targeted inhibition of airway DUOX1 in mice with previously established HDM-induced allergic inflammation, by intratracheal administration of DUOX1-targeted siRNA or pharmacological NADPH oxidase inhibitors, reversed most of these outcomes. Our findings indicate an important function for DUOX1 in allergic inflammation related to persistent EGFR activation and suggest that DUOX1 targeting may represent an attractive strategy in asthma management. Find the latest version: https://jci.me/88811/pdf RESEARCH ARTICLE DUOX1 mediates persistent epithelial EGFR activation, mucous cell metaplasia, and airway remodeling during allergic asthma Aida Habibovic,1 Milena Hristova,1 David E.